Osteoarticular Expression of XXXX in an Experimental Model of Arthritis.

@entity19 @entity64430 @entity75 @entity1753 @entity637 @entity309
Background. @entity1753 ( @entity1753 ), a @entity19 experimental disease model induced by immunization with type II collagen (CII), is used to evaluate novel therapeutic strategies for @entity309 . Adult stem cell marker @entity64430 ( @entity64430 ) plays an important role in regulating the maintenance and differentiation of stem/precursor cells. The objectives of this investigation were to perform a morphological study of the experimental @entity1753 model, evaluate the effect of @entity637 -blocker (etanercept) treatment, and determine the immunohistochemical expression of @entity64430 protein. Methods. @entity1753 was induced in 50 male DBA1/J @entity19 for analyses of tissue and serum cytokine; clinical and morphological lesions in limbs; and immunohistochemical expression of @entity64430 . Results. Clinically, @entity637 -blocker treatment attenuated @entity1753 on day 32 after immunization (P < 0.001). @entity64430 protein expression was significantly higher in joints damaged by @entity1753 than in those with no lesions (P < 0.0001) and was related to the severity of the lesions (Spearman's rho = 0.775, P = 0.0001). Conclusions. Treatment with etanercept attenuates @entity75 in the @entity19 @entity1753 model. Osteoarticular expression of @entity64430 protein is increased in joints with @entity1753 and absent in nonlesioned joints, suggesting that this protein is expressed when the lesion is produced in order to favor tissue repair.
